世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
 Oral Macromolecular Formulation Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
The global oral macromolecule formulation market is experiencing significant growth, driven by innovations in drug delivery systems and rising demand for non-invasive treatment options. According t... もっと見る
※当ページの内容はウェブ更新時の情報です。
SummaryThe global oral macromolecule formulation market is experiencing significant growth, driven by innovations in drug delivery systems and rising demand for non-invasive treatment options. According to a new industry report, the market is projected to grow from a value of approximately US$ 20 Mn in 2025 to US$ 28.5 Mn by 2032, expanding at a steady CAGR of 5.19% during the forecast period.Market Insights Oral macromolecule formulations offer a breakthrough in administering biologic therapies such as peptides and proteins. Traditionally limited to injection-based routes, macromolecules are now being explored for oral delivery due to advancements in drug delivery technologies. Oral formulations provide an ideal route due to enhanced patient compliance, reduced risk of infection, and improved stability. With increasing demand for user-friendly drug delivery methods, the market is gaining momentum across several therapeutic areas. Market Drivers The market is primarily driven by the rising global prevalence of chronic diseases such as diabetes and inflammatory bowel disease, where conventional therapies fall short in convenience and patient compliance. The discomfort, anxiety, and healthcare risks associated with injectables have created a significant push toward oral delivery solutions. Moreover, growing geriatric populations across major economies are fostering demand for easy-to-administer therapeutic options, propelling market expansion. Additionally, nanotechnology has emerged as a pivotal enabler for overcoming challenges in oral macromolecule delivery. Advanced carriers such as liposomes, nanoemulsions, dendrimers, and polymeric nanoparticles are being explored to enhance drug solubility, stability, and bioavailability. Business Opportunity Pharmaceutical manufacturers and contract research organizations are increasingly investing in R&D to develop oral formulations of traditionally injectable biologics. The shift toward outsourcing and the emergence of new drug delivery platforms provide a strong business case for market players. Companies that focus on innovation in enteric-coated systems, protease inhibitors, and structural modifications of peptides and proteins are expected to gain a competitive advantage. The growing demand for self-administration and cost-effective therapies in low-income regions further supports the market outlook. With global diabetes cases projected to rise, the potential adoption of oral insulin and other peptide-based therapies presents a lucrative opportunity for formulation specialists and biopharma innovators. Regional Analysis The United States is expected to maintain a dominant position in the global oral macromolecule formulation market, driven by a rising elderly population, a strong biopharmaceutical R&D ecosystem, and favorable regulatory support. The country is projected to contribute significantly to market revenues through 2032. Germany is emerging as a high-potential market in Europe due to increasing research activities focused on intestinal drug transport mechanisms and novel drug delivery technologies. Government and academic initiatives are fostering a conducive environment for innovation. China, on the other hand, is witnessing rapid growth owing to national funding programs aimed at enhancing biologics delivery technologies. The surge in chronic disease burden, along with expanded outsourcing capacities for biopharmaceuticals, is positioning China as a key growth market in Asia. Key Players The global oral macromolecule formulation market features a mix of established pharmaceutical players and emerging biotechnology firms. Companies are entering into strategic alliances to commercialize novel oral biologics and secure supply chain resilience. Some of the prominent players in the market include: • Catalent, Inc. – Entered into a commercial supply agreement with Phathom Pharmaceuticals for an innovative orally active treatment for gastrointestinal disorders. • Diabetology Ltd. – Successfully conducted a phase 2b trial for its oral insulin product, Capsulin™, targeting type 2 diabetes patients. • UPM Pharmaceuticals – Known for its expertise in advanced formulation and manufacturing services tailored for oral macromolecule delivery systems. These companies are actively investing in facility expansions, research partnerships, and global marketing strategies to enhance their market presence and meet the growing demand. Segmentation The global oral macromolecule formulation market is segmented as follows: By Indication: • Inflammatory Bowel Disorder • Crohn’s Disease • Ulcerative Colitis • Diabetes • Others By End User: • Biopharmaceutical Companies • Academic and Research Institutes By Region: • North America • Latin America • Europe • South Asia • East Asia • Oceania • Middle East & Africa Table of Contents1. Executive Summary1.1. Global Oral Macromolecular Formulation Market Snapshot 1.2. Future Projections 1.3. Key Market Trends 1.4. Regional Snapshot, by Value, 2025 1.5. Analyst Recommendations 2. Market Overview 2.1. Market Definitions and Segmentations 2.2. Market Dynamics 2.2.1. Drivers 2.2.2. Restraints 2.2.3. Market Opportunities 2.3. Value Chain Analysis 2.4. Porter’s Five Forces Analysis 2.5. COVID-19 Impact Analysis 2.5.1. Supply 2.5.2. Demand 2.6. Impact of Ukraine-Russia Conflict 2.7. Economic Overview 2.7.1. World Economic Projections 2.8. PESTLE Analysis 3. Global Oral Macromolecular Formulation Market Outlook, 2019-2032 3.1. Global Oral Macromolecular Formulation Market Outlook, by Indication, Value (US$ Mn), 2019-2032 3.1.1. Key Highlights 3.1.1.1. Inflammatory Bowel Disorder 3.1.1.1.1. Crohn’s Disease 3.1.1.1.2. Ulcerative Colitis 3.1.1.2. Diabetes 3.1.1.3. Others 3.2. Global Oral Macromolecular Formulation Market Outlook, by End User, Value (US$ Mn), 2019-2032 3.2.1. Key Highlights 3.2.1.1. Biopharmaceutical Companies 3.2.1.2. Academic and Research Institutes 3.3. Global Oral Macromolecular Formulation Market Outlook, by Region, Value (US$ Mn), 2019-2032 3.3.1. Key Highlights 3.3.1.1. North America 3.3.1.2. Europe 3.3.1.3. Asia Pacific 3.3.1.4. Latin America 3.3.1.5. Middle East & Africa 4. North America Oral Macromolecular Formulation Market Outlook, 2019-2032 4.1. North America Oral Macromolecular Formulation Market Outlook, by Indication, Value (US$ Mn), 2019-2032 4.1.1. Key Highlights 4.1.1.1. Inflammatory Bowel Disorder 4.1.1.1.1. Crohn’s Disease 4.1.1.1.2. Ulcerative Colitis 4.1.1.2. Diabetes 4.1.1.3. Others 4.2. North America Oral Macromolecular Formulation Market Outlook, by End User, Value (US$ Mn), 2019-2032 4.2.1. Key Highlights 4.2.1.1. Biopharmaceutical Companies 4.2.1.2. Academic and Research Institutes 4.2.2. BPS Analysis/Market Attractiveness Analysis 4.3. North America Oral Macromolecular Formulation Market Outlook, by Country, Value (US$ Mn), 2019-2032 4.3.1. Key Highlights 4.3.1.1. U.S. Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2019-2032 4.3.1.2. U.S. Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2019-2032 4.3.1.3. Canada Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2019-2032 4.3.1.4. Canada Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2019-2032 4.3.2. BPS Analysis/Market Attractiveness Analysis 5. Europe Oral Macromolecular Formulation Market Outlook, 2019-2032 5.1. Europe Oral Macromolecular Formulation Market Outlook, by Indication, Value (US$ Mn), 2019-2032 5.1.1. Key Highlights 5.1.1.1. Inflammatory Bowel Disorder 5.1.1.1.1. Crohn’s Disease 5.1.1.1.2. Ulcerative Colitis 5.1.1.2. Diabetes 5.1.1.3. Others 5.2. Europe Oral Macromolecular Formulation Market Outlook, by End User, Value (US$ Mn), 2019-2032 5.2.1. Key Highlights 5.2.1.1. Biopharmaceutical Companies 5.2.1.2. Academic and Research Institutes 5.2.2. BPS Analysis/Market Attractiveness Analysis 5.3. Europe Oral Macromolecular Formulation Market Outlook, by Country, Value (US$ Mn), 2019-2032 5.3.1. Key Highlights 5.3.1.1. Germany Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2019-2032 5.3.1.2. Germany Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2019-2032 5.3.1.3. U.K. Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2019-2032 5.3.1.4. U.K. Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2019-2032 5.3.1.5. France Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2019-2032 5.3.1.6. France Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2019-2032 5.3.1.7. Italy Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2019-2032 5.3.1.8. Italy Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2019-2032 5.3.1.9. Turkey Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2019-2032 5.3.1.10. Turkey Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2019-2032 5.3.1.11. Russia Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2019-2032 5.3.1.12. Russia Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2019-2032 5.3.1.13. Rest of Europe Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2019-2032 5.3.1.14. Rest of Europe Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2019-2032 5.3.2. BPS Analysis/Market Attractiveness Analysis 6. Asia Pacific Oral Macromolecular Formulation Market Outlook, 2019-2032 6.1. Asia Pacific Oral Macromolecular Formulation Market Outlook, by Indication, Value (US$ Mn), 2019-2032 6.1.1. Key Highlights 6.1.1.1. Inflammatory Bowel Disorder 6.1.1.1.1. Crohn’s Disease 6.1.1.1.2. Ulcerative Colitis 6.1.1.2. Diabetes 6.1.1.3. Others 6.2. Asia Pacific Oral Macromolecular Formulation Market Outlook, by End User, Value (US$ Mn), 2019-2032 6.2.1. Key Highlights 6.2.1.1. Biopharmaceutical Companies 6.2.1.2. Academic and Research Institutes 6.2.2. Others BPS Analysis/Market Attractiveness Analysis 6.3. Asia Pacific Oral Macromolecular Formulation Market Outlook, by Country, Value (US$ Mn), 2019-2032 6.3.1. Key Highlights 6.3.1.1. China Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2019-2032 6.3.1.2. China Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2019-2032 6.3.1.3. Japan Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2019-2032 6.3.1.4. Japan Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2019-2032 6.3.1.5. South Korea Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2019-2032 6.3.1.6. South Korea Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2019-2032 6.3.1.7. India Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2019-2032 6.3.1.8. India Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2019-2032 6.3.1.9. Southeast Asia Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2019-2032 6.3.1.10. Southeast Asia Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2019-2032 6.3.1.11. Rest of Asia Pacific Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2019-2032 6.3.1.12. Rest of Asia Pacific Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2019-2032 6.3.2. BPS Analysis/Market Attractiveness Analysis 7. Latin America Oral Macromolecular Formulation Market Outlook, 2019-2032 7.1. Latin America Oral Macromolecular Formulation Market Outlook, by Indication, Value (US$ Mn), 2019-2032 7.1.1. Key Highlights 7.1.1.1. Inflammatory Bowel Disorder 7.1.1.1.1. Crohn’s Disease 7.1.1.1.2. Ulcerative Colitis 7.1.1.2. Diabetes 7.1.1.3. Others 7.2. Latin America Oral Macromolecular Formulation Market Outlook, by End User, Value (US$ Mn), 2019-2032 7.2.1. Key Highlights 7.2.1.1. Biopharmaceutical Companies 7.2.1.2. Academic and Research Institutes 7.2.2. BPS Analysis/Market Attractiveness Analysis 7.3. Latin America Oral Macromolecular Formulation Market Outlook, by Country, Value (US$ Mn), 2019-2032 7.3.1. Key Highlights 7.3.1.1. Brazil Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2019-2032 7.3.1.2. Brazil Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2019-2032 7.3.1.3. Mexico Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2019-2032 7.3.1.4. Mexico Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2019-2032 7.3.1.5. Argentina Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2019-2032 7.3.1.6. Argentina Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2019-2032 7.3.1.7. Rest of Latin America Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2019-2032 7.3.1.8. Rest of Latin America Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2019-2032 7.3.2. BPS Analysis/Market Attractiveness Analysis 8. Middle East & Africa Oral Macromolecular Formulation Market Outlook, 2019-2032 8.1. Middle East & Africa Oral Macromolecular Formulation Market Outlook, by Indication, Value (US$ Mn), 2019-2032 8.1.1. Key Highlights 8.1.1.1. Inflammatory Bowel Disorder 8.1.1.1.1. Crohn’s Disease 8.1.1.1.2. Ulcerative Colitis 8.1.1.2. Diabetes 8.1.1.3. Others 8.2. Middle East & Africa Oral Macromolecular Formulation Market Outlook, by End User, Value (US$ Mn), 2019-2032 8.2.1. Key Highlights 8.2.1.1. Biopharmaceutical Companies 8.2.1.2. Academic and Research Institutes 8.2.2. BPS Analysis/Market Attractiveness Analysis 8.3. Middle East & Africa Oral Macromolecular Formulation Market Outlook, by Country, Value (US$ Mn), 2019-2032 8.3.1. Key Highlights 8.3.1.1. GCC Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2019-2032 8.3.1.2. GCC Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2019-2032 8.3.1.3. South Africa Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2019-2032 8.3.1.4. South Africa Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2019-2032 8.3.1.5. Egypt Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2019-2032 8.3.1.6. Egypt Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2019-2032 8.3.1.7. Nigeria Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2019-2032 8.3.1.8. Nigeria Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2019-2032 8.3.1.9. Rest of Middle East & Africa Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2019-2032 8.3.1.10. Rest of Middle East & Africa Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2019-2032 8.3.2. BPS Analysis/Market Attractiveness Analysis 9. Competitive Landscape 9.1. Manufacturer vs by End User Heatmap 9.2. Company Market Share Analysis, 2025 9.3. Competitive Dashboard 9.4. Company Profiles 9.4.1. Catalent, Inc 9.4.1.1. Company Overview 9.4.1.2. Product Portfolio 9.4.1.3. Financial Overview 9.4.1.4. Business Strategies and Development 9.4.2. Diabetology Ltd 9.4.2.1. Company Overview 9.4.2.2. Product Portfolio 9.4.2.3. Financial Overview 9.4.2.4. Business Strategies and Development 9.4.3. UPM Pharmaceuticals 9.4.3.1. Company Overview 9.4.3.2. Product Portfolio 9.4.3.3. Financial Overview 9.4.3.4. Business Strategies and Development 10. Appendix 10.1. Research Methodology 10.2. Report Assumptions 10.3. Acronyms and Abbreviations
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医療IT）の最新刊レポート
Fairfield Market Research社の ヘルスケアIT分野 での最新刊レポート
本レポートと同じKEY WORD（industry）の最新刊レポート
よくあるご質問Fairfield Market Research社はどのような調査会社ですか?Fairfield Market Researchでは、最新かつ最も関連性の高い市場データと洞察に満ちた詳細なレポートを発行しています。広範囲にわたり、業界動向や市場ベースのデータを含んでおり、顧客が... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|
